EMA — authorised 9 December 2021
- Marketing authorisation holder: PFIZER EUROPE MA EEIG
- Status: approved
🇪🇺 Cibinqo in European Union
EMA authorised Cibinqo on 9 December 2021
Marketing authorisations
EMA — authorised 9 December 2021
- Application: EMEA/H/C/005452
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Local brand name: Cibinqo
- Indication: Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
- Status: approved
Cibinqo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Cibinqo approved in European Union?
Yes. EMA authorised it on 9 December 2021; EMA authorised it on 9 December 2021.
Who is the marketing authorisation holder for Cibinqo in European Union?
PFIZER EUROPE MA EEIG holds the EU marketing authorisation.